Camptothecin and mitomycin combination chemotherapy on ovarian clear cell carcinoma with multiple systemic metastases.
Ovarian clear cell carcinoma is known for decreased responsiveness to most anticancer drugs, and the prognosis of patients with ovarian clear cell tumors is very poor. We report such a patient with multiple systemic metastases who showed a complete response to combined camptothecin and mitomycin chemotherapy. During therapy, clinical drug-resistance was observed transiently, but response was restored by intermittent administrations of camptothecin. Such combination chemotherapy may be a useful alternative regimen for advanced and/or metastatic ovarian clear cell carcinoma.
Tanaka
T
T
Department of Obstetrics and Gynecology, Osaka City University Medical School, Japan.
Umesaki
N
N
Ogita
S
S
D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy* / Q000556:secondary; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary
D016685:Mitomycin; D002166:Camptothecin